If you’ve been navigating fertility conversations after 35, you may have encountered the term “AMH” — Anti-Müllerian Hormone. It’s one of the most commonly discussed markers of ovarian reserve, and for many women, a single number on a lab report can spark a wave of questions, hopes, or concerns. Understanding what AMH actually measures — and what it doesn’t — can help provide helpful context for those conversations with your healthcare provider.
Ovarian reserve is a broad term referring to the quantity and quality of a woman’s remaining eggs. AMH is produced by small follicles in the ovaries and is currently considered one of the more reliable indirect indicators of how many eggs remain. However, research consistently emphasizes that AMH is one piece of a larger picture — not a definitive fertility verdict.
This article explores what current evidence says about AMH levels after 35, how they’re interpreted, and what questions might be worth discussing with a reproductive specialist.
What Research Shows About AMH and Age
AMH levels naturally decline with age as the ovarian follicle pool decreases. According to research published through the National Institutes of Health, AMH concentrations typically begin declining gradually in the late 20s and more noticeably in the mid-30s and beyond. By the early 40s, many women have measurably lower AMH levels compared to their younger counterparts.
Studies suggest that by age 35, the median AMH level is approximately 1.5–2.5 ng/mL, though individual variation is considerable. Some women at 38 have levels similar to those of a 30-year-old, while others see a steeper decline earlier. This variability is an important reason why AMH alone cannot predict fertility outcomes on an individual basis.
What the research does consistently show is that AMH correlates reasonably well with the ovarian response to fertility treatments such as IVF — women with lower AMH tend to produce fewer eggs during stimulation. However, egg quality, which is central to conception success, is not reliably reflected by AMH levels alone.
How AMH Levels Are Interpreted
AMH is typically measured through a blood test that can be done at any point in the menstrual cycle, unlike some other fertility hormones. Results are usually expressed in ng/mL or pmol/L, and labs may categorize them as low, normal, or high — though reference ranges vary between laboratories, which is worth noting when comparing results from different providers.
A commonly referenced framework suggests:
- Above 1.0 ng/mL — generally considered normal to good ovarian reserve for women over 35
- 0.5–1.0 ng/mL — may indicate diminished ovarian reserve; often prompts further evaluation
- Below 0.5 ng/mL — associated with low ovarian reserve, though conception is still possible
That said, these thresholds are not definitive cutoffs. Many women with “low” AMH have conceived naturally or with assistance, while some with “normal” levels have faced fertility challenges. If you’re reviewing AMH results, understanding your broader fertility picture alongside this number is essential.
What AMH Does Not Tell You
One of the most important points research emphasizes is that AMH does not measure egg quality — and egg quality is arguably the most significant factor in conception success and pregnancy outcomes, particularly after 35. A woman may have a relatively high AMH but still face challenges if chromosomal abnormalities in eggs are a factor (which becomes more common with age).
AMH also does not:
- Predict whether you will or won’t conceive naturally
- Determine the optimal timing for trying to conceive
- Assess the health of the uterus or fallopian tubes
- Account for male-factor fertility considerations
Fertility specialists often use AMH in combination with an antral follicle count (AFC) via ultrasound and other hormonal assessments (like FSH and estradiol on day 3 of the cycle) to build a more complete picture. No single marker tells the whole story.
AMH and Fertility Decisions After 35
For women over 35 who are planning to try to conceive, AMH testing is sometimes recommended earlier in the process than for younger women. The American College of Obstetricians and Gynecologists notes that while age itself is a factor, individual variation means that evaluation rather than assumption is the most useful approach.
Some women pursue AMH testing to inform decisions about egg freezing, timing of trying to conceive, or whether to consult a reproductive endocrinologist sooner. Research suggests that for women considering fertility preservation, earlier consultation may allow more options — though individual circumstances vary significantly and decisions are deeply personal.
A lower-than-expected AMH result can understandably be emotionally difficult to receive. It’s worth remembering that these numbers reflect statistical patterns across populations, not individual outcomes. Many women with low AMH conceive, and many choose to explore a range of paths forward. Connecting with a fertility counselor or therapist alongside a medical provider can also be valuable during this process, as the emotional aspects of the TTC journey after 35 are real and significant.
When to Talk to a Healthcare Provider About AMH
Current guidelines generally suggest that women over 35 who have been trying to conceive for six months without success seek a fertility evaluation — sooner than the one-year recommendation for younger women. AMH testing may be part of that evaluation, but it’s typically interpreted alongside other assessments and the full clinical picture.
If you have conditions such as polycystic ovarian syndrome (PCOS), endometriosis, a history of ovarian surgery, or known genetic conditions that may affect ovarian function, discussing AMH testing with your provider earlier may be appropriate. Your provider can help determine whether and when AMH testing is relevant to your situation.
Frequently Asked Questions
Can you improve AMH levels?
Research on AMH modification is limited and mixed. Some studies have explored whether certain supplements or lifestyle factors might influence AMH, but current evidence does not support any reliable method of significantly raising AMH levels. If this is a concern, a reproductive endocrinologist can offer the most current, individualized guidance.
Is AMH testing recommended for all women over 35?
AMH testing is not universally recommended as a routine screening for all women. It is most commonly ordered in the context of a fertility evaluation, when considering egg freezing, or when clinical factors suggest its usefulness. Your healthcare provider can help determine whether testing is appropriate for your specific situation.
Can a low AMH mean I can’t conceive naturally?
A low AMH does not mean conception is impossible. Many women with low AMH have conceived naturally or with fertility support. AMH reflects ovarian reserve quantity but does not directly measure fertility potential on an individual basis. A reproductive specialist can provide a more complete evaluation and discuss appropriate next steps.
How often should AMH be retested?
AMH levels generally decline gradually over time, so retesting is sometimes done annually or as part of ongoing fertility monitoring. Individual circumstances vary, and your healthcare provider can advise on whether and how often retesting makes sense in your case.
Key Takeaways
- AMH is one indicator of ovarian reserve but does not predict individual fertility outcomes or egg quality.
- AMH levels naturally decline with age, with notable changes typically beginning in the mid-to-late 30s, though individual variation is considerable.
- A lower AMH does not mean conception is impossible — many women with low AMH conceive naturally or with assistance.
- AMH is most informative when interpreted alongside other fertility assessments by a qualified specialist.
- Women over 35 experiencing fertility concerns are generally encouraged to seek evaluation after six months of trying, rather than waiting a full year.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.